Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation

Authors

  • K. G. M. M. Alberti,

    1. Department of Endocrinology and Metabolic Medicine, St Mary's Hospital, London, UK and International Diabetes Institute, Caulfield, Australia
    Search for more papers by this author
  • P. Zimmet,

    1. Department of Endocrinology and Metabolic Medicine, St Mary's Hospital, London, UK and International Diabetes Institute, Caulfield, Australia
    Search for more papers by this author
  • J. Shaw

    1. Department of Endocrinology and Metabolic Medicine, St Mary's Hospital, London, UK and International Diabetes Institute, Caulfield, Australia
    Search for more papers by this author

  • Consultant to writing group: S. M. Grundy. The IDF Consensus Meeting Faculty comprised the three authors plus: P. Aschner, B. Balkau, P. Bennett, E. Boyko, J. Brunzell, J. Chan, R. DeFronzo, J-P. Després, L. Groop, M. Laakso, J. C. Mbanya, C. Y. Pan, A. Ramachandran, E. Standl, M. Stern, J. Tuomilehto and N. Unwin. Contributors but unable to attend consensus meeting: P. Barter, P. Lefèbvre and Y. Matsuzawa.

K. George M. M. Alberti, Department of Endocrinology and Metabolic Medicine, Mint Wing, St Mary's Hospital, Praed Street, London W2 1NY, UK. E-mail: george.alberti@ncl.ac.uk

Abstract

Aims  To establish a unified working diagnostic tool for the metabolic syndrome (MetS) that is convenient to use in clinical practice and that can be used world-wide so that data from different countries can be compared. An additional aim was to highlight areas where more research into the MetS is needed.

Participants  The International Diabetes Federation (IDF) convened a workshop held 12–14 May 2004 in London, UK. The 21 participants included experts in the fields of diabetes, public health, epidemiology, lipidology, genetics, metabolism, nutrition and cardiology. There were participants from each of the five continents as well as from the World Health Organization (WHO) and the National Cholesterol Education Program—Third Adult Treatment Panel (ATP III). The workshop was sponsored by an educational grant from AstraZeneca Pharmaceuticals.

Consensus process  The consensus statement emerged following detailed discussions at the IDF workshop. After the workshop, a writing group produced a consensus statement which was reviewed and approved by all participants.

Conclusions  The IDF has produced a new set of criteria for use both epidemiologically and in clinical practice world-wide with the aim of identifying people with the MetS to clarify the nature of the syndrome and to focus therapeutic strategies to reduce the long-term risk of cardiovascular disease. Guidance is included on how to compensate for differences in waist circumference and in regional adipose tissue distribution between different populations. The IDF has also produced recommendations for additional criteria that should be included when studying the MetS for research purposes. Finally, the IDF has identified areas where more studies are currently needed; these include research into the aetiology of the syndrome.

Ancillary